introduction
Her-2/neu protein overexpression and/or gene amplification (i.e. Her-2/neu-positive) is observed in ∼15% of all breast cancers and is associated with a more aggressive biology and an unfavourable natural history compared with Her-2/neu-negative disease [1] . Trastuzumab (Herceptin®) is a recombinant humanized monoclonal antibody that targets the human epidermal growth factor-2 (Her-2/neu) receptor and is currently approved for the treatment of Her-2/neu-positive breast cancer [2] .
A number of randomized clinical trials have reported improved disease-free and overall survival when trastuzumab is administered concurrent with or after adjuvant chemotherapy in HER-2/neu-positive breast cancer [3] [4] [5] [6] [7] , and recent economic evaluations have also suggested acceptable value for money [8, 9] . However, these observations have been noted primarily in patient cohorts with moderate to high baseline risks of disease recurrence, as inclusion criteria for the pivotal adjuvant trastuzumab trials have generally specified nodepositive or node-negative disease with tumours of >1.0 cm (≥T1cN0). The role of adjuvant trastuzumab for patients with node-negative tumours of <1.0 cm is less clear in light of the variable 10-year baseline relapse risk (10%-30%) reported for patients with small (≤1 cm), node-negative tumours [10, 11] . Trastuzumab is not currently approved for T1bN0 tumours in most countries, although updated National Comprehensive Cancer Network (NCCN) guidelines have recommended considering adjuvant trastuzumab for node-negative tumours measuring 0.5-1.0 cm (T1bN0) given their potentially aggressive biology and uncertain relapse risk [12, 13] .
In light of this clinical uncertainty and the high acquisition costs of trastuzumab [14] , we examined the 'value for money' associated with adjuvant trastuzumab in women with T1bN0 breast cancer in terms of the likelihood of such a strategy meeting a $100 000 per quality-adjusted life year (QALY) gained cost-effectiveness threshold over a plausible range of baseline recurrence risks.
methods
An economic model was developed in Excel® (Microsoft Corporation, Redmond, WA, USA) to estimate the cumulative costs and QALYs gained with adjuvant trastuzumab, administered concurrent with or sequential to adjuvant chemotherapy in hypothetical cohorts of women with T1bN0 breast cancer following curative-intent surgical excision of their tumour. The cohorts were distinguished by age at entry into the model and included ages 40, 50, 60 and 70. The model took a state-transition approach and modelled the probability of moving among different health states within a 1-month period or cycle [15] . The costs and QALYs associated with each health state, weighted by the proportion of the cohort in each state in each cycle, were aggregated up to age 100 to represent a lifetime horizon and discounted at 3% annually.
economic model and analysis
The model considered four strategies: (i) no adjuvant chemotherapy or trastuzumab (baseline), (ii) adjuvant chemotherapy alone, (iii) adjuvant chemotherapy plus concurrent trastuzumab and (iv) adjuvant chemotherapy plus sequential trastuzumab. Patients in the sequential and concurrent trastuzumab strategies received 12 months of adjuvant trastuzumab after or with adjuvant chemotherapy as per the HERA (HERceptin Adjuvant) and joint North American trials, respectively [3, 4] . The key assumptions used in the model are outlined in Table 1 .
The primary analysis took a strict incremental approach, comparing concurrent and sequential trastuzumab plus chemotherapy to adjuvant chemotherapy alone. However, as physicians and/or patients may not consider adjuvant chemotherapy without trastuzumab in this setting, a secondary analysis took an 'all-or-nothing' approach and compared concurrent and sequential trastuzumab plus chemotherapy to no chemotherapy or trastuzumab. Although this approach conflates the benefit of chemotherapy and trastuzumab, making it impossible to consider the incremental benefit of trastuzumab relative to chemotherapy alone, it may arguably be a more relevant analysis from a clinical perspective. • Women were assumed to be pre-menopausal in the age 40 and 50 cohorts and post-menopausal in the age 60 and 70 cohorts.
• The cumulative 10-year baseline recurrence rate in T1bN0 breast cancer was assumed to be up to 40%.
• It was assumed that there would be no new recurrences beyond year 15.
• All patients, including those in the no chemotherapy strategy, received adjuvant radiotherapy and/or endocrine therapy as appropriate. epirubicin 100 mg/m 2 and cyclophosphamide 500 mg/m 2 i.v. q 3 weekly for three cycles followed by docetaxel 100 mg/m 2 i.v. q 3 weekly for three cycles) were used in the reference case and alternative analysis, respectively, as standard chemotherapy regimens for both concurrent and sequential trastuzumab strategies in Canadian practice.
• The disease-free survival benefit of trastuzumab was assumed to persist for up to 60 months from the start of therapy (Table 2) , beyond which the relative risk of recurrence compared with chemotherapy alone was set to 1.0. The benefit of adjuvant chemotherapy, with or without trastuzumab, was fixed at 60 months.
• Patients discontinuing trastuzumab within the first 3 months of therapy were assumed to derive no additional disease-free survival benefit relative to chemotherapy alone.
• The model assumed no additional mortality as a result of trastuzumab cardiotoxicity based on current evidence from randomized clinical trials.
• Patients developing a local recurrence were assumed to be at risk of a concurrent diagnosis of distant recurrence and at increased risk of a subsequent local or distant recurrence. Patients could experience up to two local recurrences; any subsequent recurrences were assumed to be metastatic. Once a patient transitioned to metastatic disease, median survival was 21 months.
• As most of the cost studies did not report the variance of their mean cost estimates, the probabilistic modelling assumed a log-normal distribution with a standard deviation 25% of the mean for all cost parameters. Given uncertainty over the precise recurrence risk in T1bN0 breast cancer without adjuvant systemic therapy, the primary and secondary analyses were conducted as a series of probabilistic analyses over a range of possible baseline recurrence rates without chemotherapy or trastuzumab. Parameter values and distributions used in the probabilistic analyses are shown in Table 2 . The primary outcome of interest was the likelihood of each strategy meeting a $100 000 per QALY gained threshold for a range of 10-year baseline recurrence rates. Probabilities of ≥50% indicate that a strategy was likely to be cost-effective at that recurrence rate. (Probability was calculated as the proportion of iterations for a given recurrence rate with a net monetary benefit (NMB) greater than zero, where NMB = (ΔEλ) − ΔCΔE is the incremental health gain, λ the threshold cost per QALY gained (in this case, $100 000) and ΔC the incremental cost. NMB avoids many of the limitations of the conventional incremental costeffectiveness ratio (ΔC/ΔE), including a discontinuity where ΔE = 0 and an ambiguous sign on the quotient [15, 16] .) Other reported outcomes were lifetime cumulative costs and QALYs gained with each strategy relative to baseline by the recurrence rate. The likelihood of meeting a $100 000 per unadjusted life year gained threshold was considered in a sensitivity analysis.
health states
All patients entered the model in the 'disease-free state' and were at risk of 'local recurrence', 'distant recurrence' or 'death' (Figure 1 ). Patients in local recurrence could transition to 'well following local recurrence', but patients in the distant recurrence state remained in that state until death. As patients were at increased risk of cardiotoxicity while receiving concurrent or sequential trastuzumab, the disease-free, local recurrence, well following local recurrence and distant recurrence health states were stratified by 'experienced with or without cardiotoxicity'. Patients developing trastuzumab-related symptomatic cardiotoxicity discontinued trastuzumab therapy, but could move to the cardiotoxicity-free strata in subsequent months based on transition probabilities derived from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial [17] . Baseline utility was adjusted for patient age in each cycle, with baseline and specific health state utilities taken from the literature [18, 19] .
event rates
In the absence of precise estimates of baseline recurrence rates in T1bN0 breast cancer without adjuvant chemotherapy or trastuzumab, the analyses were conducted iteratively for 10-year baseline recurrence rates up to 40%, rather than for specific point estimates. The relative distribution of recurrences without adjuvant systemic therapy over model years 0-15 was derived from the Early Breast Cancer Trialists Collaborative Group (EBCTCG) meta-analysis [20] .
The baseline relapse risk in the model implicitly incorporated the benefit of adjuvant endocrine therapy and/or radiotherapy treatments for all patients as appropriate. The relative reduction in the risk of relapse associated with adjuvant chemotherapy in the absence of trastuzumab was based on hazard ratio estimates from Adjuvant! Online [21] for the relevant chemotherapy regimens and was stratified by pre-menopausal and post-menopausal status. The additional relative reduction in the risk of relapse and symptomatic cardiotoxicity rates associated with sequential and concurrent trastuzumab plus chemotherapy compared with chemotherapy alone were derived from the HERA trial [3] and the concurrent trastuzumab arm of the joint analysis of the NCCTG N9831 and NSABP B-31 trials, respectively [4] . The rates of chemotherapy-related adverse events, including grade 3-4 chemotherapy-induced nausea and vomiting, febrile neutropenia, chemotherapy-related congestive heart failure (CHF), acute myeloid leukaemia and myelodysplastic syndrome, were based on pooled event rates from clinical trials involving the relevant chemotherapy regimens [3] [4] [5] [6] [7] . The risk of CHF was adjusted by age, with patients older than 50 at greater risk than younger patients [5] . The risk of trastuzumab-related significant/symptomatic CHF was derived from a recent meta-analysis of cardiac dysfunction with trastuzumab in breast cancer patients [22] . All patients were also subject to an age-specific background risk of mortality derived from Statistics Canada life tables [23] .
costs
The analysis took a direct payer perspective, considering direct costs to the healthcare system and the patient. The costs of incorporating trastuzumab in the adjuvant setting, including HER-2/neu testing, acquisition costs, drug administration, supportive medications and cardiac monitoring, were taken from previous cost studies conducted by members of the study team [14, 24] . The costs of palliative trastuzumab were based on a local study of trastuzumab utilization in the palliative setting [25] . Other costs incorporated in the model were derived from the literature, including costs for local and distant cancer recurrences as well as the cost of different chemotherapy-related adverse events, as per our previous work [26] [27] [28] [29] [30] . All costs were adjusted to 2011 Canadian dollars (CDN$1.00 = US$0.82 in terms of 2011 purchasing power parity [31] ) based on the Statistics Canada consumer price index, health and personal care component [32] .
results
The results of the primary incremental analysis, comparing sequential and concurrent trastuzumab plus chemotherapy with chemotherapy alone over a lifetime horizon, are shown in Figure 2 , stratified by strategy and age cohort. They suggest that concurrent trastuzumab plus chemotherapy had a greater than 50% likelihood of meeting a $100 000 per QALY gained threshold at 10-year baseline recurrence rates more than 29%-35% in the ages 40, 50 and 60 cohorts. The age 70 cohort did not reach a 50% likelihood over the range tested nor did any of the age cohorts under a sequential trastuzumab plus chemotherapy strategy. In a sensitivity analysis using life years rather than QALYs as the outcome measure, the minimum recurrence rates necessary to meet a $100 000 threshold were reduced to between 23% and 30% (an ∼20% relative improvement) under a concurrent strategy for the age 40, 50 and 60 cohorts and to 35% in the age 40 cohort under a sequential strategy. The other sequential strategy age cohorts did not reach a 50% likelihood. The results of the secondary 'all-or-nothing' analysis, comparing sequential and concurrent trastuzumab plus chemotherapy with baseline without chemotherapy or trastuzumab, are shown in Figure 3 . They suggest that compared with baseline, the age cohorts in both the concurrent and the sequential strategies would have at least a 50% likelihood of meeting a $100 000 cost per QALY gained threshold at 10-year baseline recurrence rates between 10% and 28%. Using life years rather than QALYs reduced the minimum necessary recurrence rates slightly to between 8% and 22%.
Incremental lifetime QALY gains from adjuvant systemic therapy increased with higher baseline recurrence risk in each age cohort, but these gains were successively smaller as age at entry to the model increased. The proportion of incremental QALY gains specifically associated with adjuvant trastuzumab also increased with higher baseline recurrence risk, but was <50% of the total QALY gains from adjuvant therapy over the entire recurrence range tested in all four age cohorts. The total expected cost of adjuvant systemic therapy, with or without adjuvant trastuzumab, decreased slightly as the recurrence risk increased. The proportion of the total costs associated with trastuzumab also declined as the recurrence risk increased, but this proportion was always >90%. The lifetime incremental costs and QALYs associated with each adjuvant systemic strategy, over a range of 10-year baseline recurrence rates and stratified by age cohort, are shown in the supplementary Appendix, available at Annals of Oncology online.
Sensitivity analysis showed that utilizing an alternative chemotherapy regimen (Table 1) did not improve the likelihood of concurrent or sequential trastuzumab meeting a $100 000 per QALY gained threshold.
conclusions
The adoption of costly interventions commonly relies on clinical assessments of the benefit/risk profile and economic evaluations of the value for money. Adjuvant trastuzumab is currently recommended for women with moderate to high risk HER-2/neu-positive breast cancers, including nodepositive cancers and node-negative cancers with larger tumour sizes (≥T1cN0), based on its favourable benefit/risk profile and acceptable value for money. The role of adjuvant trastuzumab in women with T1bN0 breast cancers is less clear given the variable relapse risk reported to date for these smaller tumours, which were not routinely included in the relevant clinical trials of adjuvant trastuzumab, and the resultant economic uncertainties surrounding its value for money. This economic evaluation modelled the probability of sequential and concurrent adjuvant trastuzumab plus chemotherapy meeting a $100 000 per QALY gained threshold over a plausible range of recurrence risks for Her-2/neu breast cancer with T1bN0 disease. The primary incremental analysis, using chemotherapy alone as the comparator, found that concurrent trastuzumab was likely to meet a $100 000 per QALY gained threshold at 10-year baseline recurrence risks >29%-35%, depending on age. Although the expected costs of adjuvant therapy were very similar across the age cohorts, patients in the younger cohorts had greater lifetime QALY gains than patients in the older cohorts and were therefore likely to meet a $100 000 threshold at lower baseline recurrence rates.
The secondary 'all-or-nothing' analysis, comparing trastuzumab and chemotherapy with no adjuvant chemotherapy strategy, was much more favourable for both concurrent and sequential trastuzumab strategies, but would only be relevant if chemotherapy would not be considered in clinical practice without adjuvant trastuzumab for women with Her-2/neu-positive breast cancers. Adjuvant chemotherapy, though, was the comparator arm in clinical trials of adjuvant trastuzumab plus chemotherapy for Her-2/neu-positive breast cancers with tumours of >1 cm (≥ T1c tumours) [3, 4] . Moreover, as illustrated in the online appendix, available at Annals of Oncology online, the QALY gains associated with adjuvant systemic therapy were predominantly driven by chemotherapy without trastuzumab over the entire recurrence range tested. Although no adjuvant chemotherapy may be a reasonably clinical strategy in smaller Her-2/neu-positive breast cancers, there is little indication that it is an appropriate 'economic' comparator when seeking to consider the incremental cost and benefit of concurrent or sequential trastuzumab.
The aggregate cost of adjuvant systemic therapy, with or without adjuvant trastuzumab, decreased as the baseline risk of recurrence increased, suggesting that the upfront costs of adjuvant therapy may be offset to some degree by relative savings associated with the number of recurrences avoided. Despite these declining costs, and the increasing proportion of incremental QALYs associated with adjuvant trastuzumab as baseline risk increased, trastuzumab was consistently associated with a disproportionate share of the costs of adjuvant therapy relative to incremental QALY gains, particularly at lower recurrence rates. Note, though, that the analysis only considered direct costs to payers, including indirect societal costs would most likely increase the net savings from recurrences avoided, and therefore, improve the relative costeffectiveness of adjuvant therapy.
As in all economic evaluations, our results may not be generalizable to all health care jurisdictions given the potential for substantial differences in costs and/or clinical practice compared with the Canadian health care system. As well, other jurisdictions may have different requirements for reimbursement, which may or may not include the explicit evaluation of value for money. We were also forced to rely on a number of assumptions due to sparse clinical data around T1bN0 cancers, including estimates of baseline relapse risks without systemic therapy. The observed favourability of concurrent over sequential trastuzumab was based on an indirect across-trials comparison that incorporated estimates of treatment benefit from multiple studies [4] , although this was concordant with preliminary results from the one randomized clinical trial that directly examined concurrent versus sequential trastuzumab [33] . However, our probabilistic analysis over a range of baseline relapse risks allowed for variability around input parameters, including the underlying baseline recurrence risk, the relative risk reduction associated with concurrent and sequential trastuzumab and the duration of trastuzumab benefit. This analysis shows that concurrent trastuzumab plus adjuvant chemotherapy appears to offer a favourable value for money at the upper ranges of baseline recurrence risks reported to date, particularly in younger patients, although 
